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Remote Triage Incorporating Symptom- Based Risk Stratification 
for Suspected Head and Neck Cancer Referrals: A Prospective 
Population- Based Study
John C. Hardman, MBChB 1; Theofano Tikka, MBChB 2; Vinidh Paleri, MS 1; and on behalf of ENT UK, BAHNO and 
INTEGRATE (The UK ENT Trainee Research Network)
BACKGROUND: Remote triage for suspected head and neck cancer (HNC) referrals was adopted by many institutions during the initial 
peak of the coronavirus disease 2019 pandemic. Its safety in this population has not been established. METHODS: A 16- week, prospec-
tive, multicenter national service evaluation was started on March 23, 2020. Suspected HNC referrals undergoing remote triage in UK 
secondary care centers were identified and followed up for a minimum of 6 months to record the cancer status. Triage was supported 
by risk stratification using a validated calculator. RESULTS: Data for 4568 cases were submitted by 41 centers serving a population of 
approximately 26 million. These represented 14.1% of the predicted maximum referrals for this population outside of pandemic times, 
and this gave the study a margin of error of 1.34% at 95% confidence. Completed 6- month follow- up data were available for 99.8% with 
an overall cancer rate of 5.6% (254 of 4557). The rates of triage were as follows: urgent imaging investigation, 25.4% (n = 1156); urgent 
face- to- face review, 27.8%; (n = 1268); assessment deferral, 30.3% (n = 1382); and discharge, 16.4% (n = 749). The corresponding missed 
cancers rates were 0.5% (5 of 1048), 0.3% (3 of 1149), 0.9% (12 of 1382), and 0.9% (7 of 747; P = .15). The negative predictive value for 
a nonurgent triage outcome and no cancer diagnosis was 99.1%. Overall harm was reported in 0.24% (11 of 4557) and was highest for 
deferred assessments (0.58%; 8 of 1382). CONCLUSIONS: Remote triage, incorporating risk stratification, may facilitate targeted inves-
tigations for higher risk patients and prevent unnecessary hospital attendance for lower risk patients. The risk of harm is low and may be 
reduced further with appropriate safety netting of deferred appointments. Cancer 2021;0:1-13. © 2021 The Authors. Cancer published 
by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the terms of the Creat ive Commo ns 
Attri butio n- NonCo mmerc ial- NoDerivs License, which permits use and distribution in any medium, provided the original work is properly 
cited, the use is non- commercial and no modifications or adaptations are made. 
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Lay Summary: 
• This large national study observed the widespread adoption of telephone assessment (supported by a risk calculator) of patients re-
ferred to hospital specialists with suspected head and neck cancer during the initial peak of the coronavirus disease 2019 pandemic.
• The authors identified 4568 patients from 41 UK centers (serving a population of more than 26 million people) who were followed up 
for a minimum of 6 months.
• Late cancers were identified, whether reviewed or investigated urgently (0.4%) or nonurgently (0.9%), but the overall rate of harm was 
low (0.2%), with the highest rate being seen with deferred appointments (0.6%). 
KEYWORDS: harm, multicenter, national, observational, telemedicine.
INTRODUCTION
The emergence of coronavirus disease 2019 (COVID- 19) 
in early 2020 led to significant changes in the normal 
practices for the diagnosis and management of cancer. 
This was especially pronounced in specialties such as ear, 
nose, and throat (ENT), head and neck surgery, and oral 
health, where aerosol- generating procedures were com-
monly performed.1,2 Patients and health care services 
alike had an interest in avoiding hospital attendance to re-
duce the potential for spreading infection and to preserve 
resources for the pandemic response.3 Part of the shift in 
practice included a sharp uplift in the use of telemedicine 
in place of face- to- face outpatient appointments.4,5
Patients referred from primary care to secondary care 
with suspected head and neck cancer (HNC) are at par-
ticular risk of harm from changes to the standard- of- care 
diagnostic pathway. In normal times, physical examina-
tion, combined with flexible transnasal endoscopy of the 
upper aerodigestive tract where indicated, is considered 
an essential facet of the new patient evaluation. Remote 
assessment necessarily forgoes this and relies on the pa-
tient history and the referral information provided by 
the primary care physician alone. However, it may also 
facilitate earlier patient contact, may use fewer outpatient 
resources, and may allow a more efficient route to targeted 
investigations in select patients.6,7 Patients with cancer 
may be diagnosed faster, and those without cancer may 
be reassured more efficiently; this provides potential ben-
efits to patients and health care services alike. However, 
remote triage was novel to most clinicians at the time it 
was widely adopted, and the safety of this practice in these 
patients had not been established. It is likely that an in-
crease in telemedicine will remain to some degree in post-
pandemic times, and so it is necessary to review its safety 
in this population.8
We had previously developed and validated a risk 
calculator (Head and Neck Cancer Risk Calculator ver-
sion 2 [HaNC- RC- v2]) based on the symptom and de-
mographic data of approximately 10,000 new patient 
referrals with suspected HNC.9 This was disseminated 
just before the worst of the disruption brought about by 
the initial peak of COVID- 19 in the United Kingdom 
and is freely available online. Communicating and under-
standing risk is an important element of shared decision- 
making between patients and clinicians in health care.10 
The use of a standardized triage system can further help in 
the understanding of the decision- making process and the 
role of clinical judgment for each patient. Effective risk 
stratification may have a prominent role in addressing a 
backlog of referrals to cancer services as resources strained 
by the pandemic recover and we refocus on the impor-
tance of valuing all lives equally.11
In the United Kingdom, since 2005, guidance from 
the National Institute for Health and Care Excellence has 
recommended that patients presenting to their primary 
care physicians with symptoms in the head and neck re-
gion suggestive of cancer be referred to secondary care via 
a rapid access pathway to be assessed within 2 weeks.12 
This pathway covers all cancers affecting the head and 
neck region, including the following: pharyngeal cancer, 
laryngeal cancer, oral cavity/lip cancer, thyroid cancer, cu-
taneous cancer, salivary gland cancer, nasal cavity/sinus 
cancer, and cancers affecting the ear. A number of other 
non- HNC malignancies may also inevitably be identified 
on this pathway if they present with symptoms in the 
head and neck (eg, thoracic lesions causing swallowing 
obstruction or hoarseness from injury to the recurrent 
laryngeal nerve and non- HNC metastasizing to cervical 
lymph nodes or lymphomas presenting as neck lumps).
In consultation with the British Association of 
Otorhinolaryngology– Head and Neck Surgery (ENT UK) 
and the British Association of Head and Neck Oncologists 
(BAHNO) and through collaboration with the UK ENT 
Trainee Research Network (INTEGRATE), a national ser-
vice evaluation was rapidly developed and implemented to 
monitor the unique shift in practice toward remote con-
sultations.13 This study aims to report the findings of this 
16- week, prospective service evaluation of remote triage of 
suspected HNC referrals conducted during the initial peak 
of the COVID- 19 pandemic in the United Kingdom.
Head and Neck Cancer Remote Triage/Hardman et al
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MATERIALS AND METHODS
The protocol for this study was published in advance at 
https://entin tegra te.co.uk. This article was prepared with ref-
erence to the Strengthening the Reporting of Observational 
Studies in Epidemiology checklist for cohort studies.14
Ethical Considerations
The Health Research Authority decision tool determined 
that the study design fell under the remit of a service eval-
uation, and so no ethical approval was required (available 
at http://hra- decis ionto ols.org.uk/resea rch/).
Study Design and Setting
A national prospective service evaluation was conducted; 
it was supported by ENT UK and BAHNO and deliv-
ered via the INTEGRATE network. All UK ENT depart-
ments were invited to participate via social media and 
mailouts from the supporting organizations. Sites could 
open at any point during the prospective data collection 
period. Registration as per local governance guidelines 
was required to participate.
Participants
Patients who were referred on the suspected HNC 
pathway to secondary care and who were prospectively 
identified and completed remote triage over a telephone 
consultation were eligible for inclusion. These patients 
were referred by primary care physicians to secondary 
care HNC specialists for further assessment without any 
upfront requirement for imaging, procedures, or biopsies 
before this assessment.
Data Collection
Cases were identified over a 16- week period between 
March 23 and July 13, 2020. The final submission of data 
was accepted after a minimum 6- month follow- up. To be 
eligible for inclusion, cases were required to have com-
plete demographic and symptom data with no null data 
points in these fields. To facilitate this, a standardized elec-
tronic case report form was created with Excel software 
(Microsoft Corporation, Redmond, Washington; see the 
supporting information); this incentivized the completion 
of data by displaying a risk stratification result from the 
HaNC- RC- v2 only if all relevant triage fields were accu-
rately filled out.9 Data were held offline at each center 
until the follow- up period had passed for all patients, 
whereupon the patient record was checked by the local 
team for a diagnosis of cancer at any time since the initial 
triage; it was classed as either on the urgent assessment 
pathway or “late” if at any time thereafter.
The following data were collected: patient demo-
graphics, smoking and alcohol history, symptoms as per 
the HaNC- RC- v2,9 triage outcome, clinician and patient 
preferences for review/investigation, cancer diagnosis 
timing, and the primary site of the cancer (if identified). 
Data were not collected on the specific type of investiga-
tion requested, the grade of the clinicians completing the 
triage consultation, or the stage of cancer at the time of 
diagnosis.
The project management team handled only ano-
nymized data, with all identifiable information removed 
before submission by the local teams. Where missing 
or ambiguous data were identified by the project man-
agement team, a query was raised with the local site to 
clarify each data point. Where missing data could not 
be resolved, that record was excluded from the relevant 
analysis.
Using the data tool with in- built risk stratification
Risk stratification was performed with the HaNC- RC- v2, 
which is open license and is freely available online at 
http://orlhe alth.com/risk- calcu lator - 2.html. This tool 
was validated in a population undergoing face- to- face 
assessment with suspected HNC. It was incorporated 
into the Excel Data Tool as a decision aid to assist ex-
perienced health care professionals in assessing patients 
after a rapid shift in practice toward remote triage as part 
of the COVID- 19 pandemic response. The algorithm for 
the calculator had been developed to deliver a negative 
predictive value (NPV) of 98.6% for those classed as low 
risk. Clinicians were instructed to consider both the clini-
cal history and the outcome of the risk stratification in 
proposing their management plan.
Data Analysis
The primary outcome was the diagnosis of cancer after a 
minimum of 6 months of follow- up. Cancers identified 
incidentally from investigations arising from the index re-
ferral but not related to the referral symptoms and cancers 
identified in the follow- up period that were not linked to 
the index referral were not included in the analysis. This 
was intended to ensure that the referral symptoms them-
selves could be relied upon as prognosticators of any sub-
sequent cancer diagnosis and, as such, was indiscriminate 
as to the ultimate site/type of cancer diagnosed.
No a priori sample size calculation was performed. 
Categorical variables were compared via the χ2 test with 
the Yates correction, with a 2- tailed P value of .05 taken as 
significant. The analysis was performed with R statistical 
software (R Foundation, Vienna, Austria).
Original Article
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Interim Reports
After 8 weeks, interim data were requested from partici-
pating centers, and a report was produced to allow rapid 
feedback of preliminary findings to the UK ENT com-
munity. The report was disseminated electronically via 
an ENT UK mailout on June 3, 2020, and was hosted 
online at https://entuk.org and https://entin tegra te.co.uk 
(see the supporting information).
RESULTS
Centers and Submissions
Final data were submitted by 41 of 47 UK centers that 
registered interest in taking part (32 in England, 6 in 
Scotland, 2 in Wales, and 1 in Northern Ireland), with 
4568 cases eligible for analysis with complete demo-
graphic and symptom data (median cases per center, 99; 
range, 10- 337; interquartile range [IQR], 40- 157). The 
median age for referrals was 58 years (range, 1- 98 years; 
IQR, 46- 69 years), and 57.1% were female (n = 2608).
The 41 centers serve a population of approximately 
26 million people (Supporting Table 1). Our data, there-
fore, represent 14.1% of the predicted maximum refer-
rals for this population and time period based on activity 
outside of pandemic conditions (referral rate, 404.5 per 
100,000; 2019- 2020)15; this allowed for a margin of error 
of 1.34% at a 95% confidence level for the study.
Data completeness
The cancer status at a minimum follow- up of 6 months 
was provided in 99.8% of the cases (n = 4557), with 11 
records having incorrect patient identifiers recorded at the 
initial triage, which precluded local follow- up. The triage 
outcome was provided for 99.7% of the cases (n = 4555), 
and the clinician advice for management was provided for 
98.5% of the cases (n = 4501).
Symptoms
Table 1 summarizes the incidence of presenting symptoms, 
smoking history, and alcohol history alongside their posi-
tive predictive values (PPVs) for cancer at any time and 
their triage outcomes. The nonnegative responses to these 
factors are presented with clinically interesting pairings in 
Figures 1 and 2. Figure 1 contrasts the incidence (inner 
ring) with the PPV (outer ring) for each factor. Figure 2 
contrasts the discharge rate (inner ring) with the rate of tri-
age directly to an investigation (outer ring) for each factor.
Diagnosis of Cancer
Table 2 summarizes the cancer status by triage outcome, 
clinician advice for assessment, and risk stratification with 
the HaNC- RC- v2. The overall rate of a cancer related to 
the referral symptoms in this population was 5.6% (254 
of 4557), with a 5.0% rate on the urgent pathway (227 of 
4568) and a 0.6% rate in the follow- up period (27 of 4330).
Triage outcome
The triage outcome indicates the decision made by the 
clinician using the information from the remote assess-
ment and the risk stratification from HaNC- RC- v2. This 
was classed as either urgent assessment (a face- to- face 
clinical assessment and/or investigation; 53.2%) or non-
urgent (deferred reviews or investigations and discharges; 
46.8%). Triage outcome (urgent vs nonurgent) and cancer 
at any time were significantly associated (9.7% vs 0.9%; 
P < .0001). The sensitivity, specificity, PPV, and NPV for 
being triaged to an urgent assessment and having a related 
cancer diagnosed at any time were 92.5%, 49.1%, 9.7%, 
and 99.1%, respectively.
Late cancers were reported in 0.9% of those triaged 
as nonurgent and in 0.4% of those assessed urgently (19 
of 2129 and 8 of 2197, respectively; P = .0439).
A more detailed breakdown by triage outcomes is 
given in Table 2. The rates of triage were as follows: ur-
gent imaging investigation, 25.4% (n = 1156); urgent 
face- to- face review, 27.8% (n = 1268); assessment defer-
ral, 30.3% (n = 1382); and discharge, 16.4% (n = 749). 
The corresponding late cancer rates were 0.5%, 0.3%, 
0.9%, and 0.9% (5 of 1048, 3 of 1149, 12 of 1382, and 
7 of 747, respectively). These rates were not significantly 
different (P = .15).
It should be noted that patients classed as nonurgent 
(deferred reviews or investigations and discharges) could 
not, by this definition, have cancers recorded as being 
found on the urgent pathway in this analysis.
Clinician advice for assessment
Clinician advice for assessment with a review/investiga-
tion was recorded as either yes (69.7%) or no (30.3%). 
Clinician advice for assessment and cancer at any time 
were significantly associated (7.3% vs 1.5%; P < .0001). 
The sensitivity, specificity, PPV, and NPV for a prefer-
ence for review/investigation and having a related cancer 
diagnosed at any time were 91.6%, 31.5%, 7.3%, and 
98.5%, respectively.
Late cancers were reported in 0.5% of those who 
were advised by their clinician for a review or investigation 
and in 0.7% of those not advised for further assessment 
(16 of 2925 and 10 of 1349, respectively; P = .5840).
It should be noted that 72.2% of those patients 
whose clinicians advised an assessment were seen urgently, 
Head and Neck Cancer Remote Triage/Hardman et al
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8 Cancer  Month 0, 2021
whereas only 10.0% of those not advised for further as-
sessment were (2265 of 3139 vs 136 of 1362). This lim-
ited the potential for the reporting of urgent cancers in 
the latter group.
Risk stratification
Risk was stratified as either high (31.3%) or low (68.7%), 
as determined by the HaNC- RC- v2. Stratification to high 
risk and a cancer at any time were significantly associated 
(13.0% vs 2.2%; P < .0001) with the following diagnos-
tic parameters: the sensitivity, specificity, PPV, and NPV 
were 73.2%, 71.1%, 13.0%, and 97.8%, respectively.
Late cancers were reported in 0.6% of the high- risk 
group versus 0.6% of the low- risk group (7 of 1249 vs 20 
of 3081; P = .9023).
It should be noted that 91.5% of the high- risk group 
were seen and/or assessed urgently, whereas only 35.7% of 
the low- risk group were (1306 of 1427 vs 1118 of 3128). 
This limited the potential for the reporting of urgent can-
cers in the low- risk group.
Primary Cancer Site
Table 3 shows the primary sites of the 254 cancers re-
ported in the study period that were related to the referral 
Figure 1. The outer ring displays the PPVs of the nonnegative responses to symptom, smoking, and alcohol triage questions, which 
are contrasted against the incidences of these responses on the inner ring. Colors besides blue in the inner- ring group together 
responses with more than 2 tiers that would compete with each other. bilat indicates bilateral; fluct./reduc., fluctuating/reducing; 
FOSIT, feeling of something in the throat; int., intermittent; mid., midline; pers., persistent; PPV, positive predictive value; unilat.; 
unilateral.
Head and Neck Cancer Remote Triage/Hardman et al
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symptoms. The median age for patients with cancer was 
65.5 years (range, 21- 94 years; IQR, 57- 73 years), and 
34.6% were female (88 of 254).
The most common cancers were oropharyngeal can-
cer (25.6%; n = 65), lymphoma (17.7%; n = 45), and 
laryngeal cancer (12.2%; n = 31). Figure 3 shows the dis-
tribution of cancers by age in comparison with the referral 
cohort as a whole.
Lymphoma, lung cancer, and esophageal cancer were 
the most common non- HNCs in the cohort. Non- HNCs 
represented 33.9% of cancers identified from these patients 
referred on the suspected HNC pathway (86 of 254).
Late Cancers and Harm
Eight of the 27 cases whose cancer was identified late 
had undergone an urgent assessment, and 4 of these 
cases were classed as low risk; 19 cases were not urgently 
assessed, and 17 of these cases were classed as low risk 
(Supporting Table 2). The treating clinicians were con-
tacted to obtain details of factors that may have con-
tributed to the late diagnosis and any perceived harm 
from the delay (defined as either a worse prognosis or 
escalated treatment). It was felt that harm had resulted 
from the late diagnosis in 0.24% of the patients triaged 
(11 of 4557: 7 HNC cases and 4 non- HNC cases), with 
the highest relative rate among deferred appointments 
at 0.58% (8 of 1382) and with lower rates in those 
discharged (0.13%; 1 of 749), triaged to an urgent in-
vestigation (0.09%; 1 of 1156), or triaged to an urgent 
face- to- face review (0.08%; 1 of 1268). The sites of the 
primary cancer for those coming to harm are identified 
in Table 3.
Figure 2. The outer ring displays the rates of triage directly to an urgent investigation for the nonnegative responses to symptom, 
smoking, and alcohol triage questions, which are contrasted against the rates of direct discharge for these responses on the inner 
ring. Colors besides blue in the inner- ring group together responses with more than 2 tiers that would compete with each other. 
bilat indicates bilateral; fluct./reduc., fluctuating/reducing; FOSIT, feeling of something in the throat; int., intermittent; mid., midline; 
pers., persistent; unilat.; unilateral.
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DISCUSSION
This is the first multicenter study to report the effectiveness 
of remote triage incorporating risk stratification in patients 
referred to secondary care with suspected HNC.16 It is also 
the first study of patients with suspected HNC to report 
medium- term outcomes to identify cancers that may have 
been missed by current diagnostic practices. This prospective 
multicenter study is uniquely placed to learn lessons from 
the changes in practice brought about by the initial peak of 
the COVID- 19 pandemic in the United Kingdom, and it 
offers significant insight into a real- world use of a remote 
triage system incorporating risk stratification in suspected 
HNC referrals. The robust, prospectively collected patient- 
level data allowed direct linkage of the referral symptoms to 
TABLE 2. Cancers by Time of Diagnosis Alongside Triage Outcomes, Clinician Advice for Assessment, and 
Results of Risk Stratification
% of All Cases
Cancers
Urgent Late Any Time
% Cancers Total % Cancers Total % Cancers Total
By triage outcome 4555 4326 4553
Urgent assessment 53.2 9.4 227 2424 0.4 8 2197 9.7 235 2424
Investigation first 25.4 9.3 108 1156 0.5 5 1048 9.8 113 1156
Investigation at any time 37.5 13.1 224 1707 0.5 8 1483 13.6 232 1707
Review first 27.8 9.4 119 1268 0.3 3 1149 9.6 122 1268
Review at any time 37.4 12.7 217 1703 0.3 5 1486 13.0 222 1703
Nonurgent 46.8 0.0 0 2131 0.9 19 2129 0.9 19 2129
Deferred 30.3 0.0 0 1382 0.9 12 1382 0.9 12 1382
Discharged 16.4 0.0 0 749 0.9 7 747 0.9 7 747
By clinician advice 4501 4274 4499
Clinician advised for 
assessment
69.7 6.8 214 3139 0.5 16 2925 7.3 230 3139
Clinician did not advise for 
assessment
30.3 0.8 11 1362 0.7 10 1349 1.5 21 1360
By risk stratification 4568 4330 4557
High risk 31.3 12.5 179 1429 0.6 7 1249 13.0 186 1428
Low risk 68.7 1.5 48 3139 0.6 20 3081 2.2 68 3129
Overall 100 5.0 227 4568 0.6 27 4330 5.6 254 4557
TABLE 3. Sites of Primary Cancer by Time of Diagnosis Alongside Proportions Found Late and Numbers 
Identified as Coming to Harm







Urgent Late Any Time
% No. % No. % No.
Oropharynx 27.3 62 11.1 3 25.6 65 4.6 1
Lymphoma 18.5 42 11.1 3 17.7 45 6.7 — 
Larynx 10.6 24 25.9 7 12.2 31 22.6 5
Thyroid 9.3 21 11.1 3 9.4 24 12.5 — 
Lung 4.8 11 18.5 5 6.3 16 31.3 1
Esophageal 4.4 10 11.1 3 5.1 13 23.1 2
Unknown primary 4.0 9 0.0 0 3.5 9 0.0 — 
Hypopharynx 3.5 8 0.0 0 3.1 8 0.0 — 
Oral cavity 3.5 8 0.0 0 3.1 8 0.0 — 
Salivary 3.5 8 0.0 0 3.1 8 0.0 — 
Skin 3.1 7 0.0 0 2.8 7 0.0 — 
Breast 1.8 4 0.0 0 1.6 4 0.0 — 
Nasal cavity 1.3 3 3.7 1 1.6 4 25.0 1
Nasopharynx 1.3 3 3.7 1 1.6 4 25.0 — 
Leukemia 0.9 2 0.0 0 0.8 2 0.0 — 
Ovarian 0.9 2 0.0 0 0.8 2 0.0 — 
Colorectal 0.4 1 0.0 0 0.4 1 0.0 — 
Liver 0.0 0 3.7 1 0.4 1 100.0 1
Prostate 0.4 1 0.0 0 0.4 1 0.0 — 
Renal 0.4 1 0.0 0 0.4 1 0.0 — 
Total 89.4 227 10.6 27 100.0 254 10.6 11
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the diagnosis of a related cancer and removed potentially 
distracting incidental cancers that may have contaminated 
similar studies relying on retrospective database queries.17
Despite the pressures on hospitals and clinicians 
during the initial peak of the COVID- 19 pandemic, there 
was widespread and meaningful engagement, with 41 
centers contributing data and nearly complete 6- month 
outcomes (99.8%). This has demonstrated stakeholder 
support for the use of a standardized symptom inventory 
to record the assessment of patients with suspected HNC.
A small proportion of patients who were assessed ur-
gently and were discharged from the urgent pathway were 
diagnosed with cancers at a later time (0.4%). Although 
this rate was lower than that for those triaged as nonur-
gent (0.9%), it has still highlighted the need for suspected 
cancer diagnostic services to be judged on medium- term 
outcomes to allow for delayed re- presentation and not to 
use the point of discharge as the definitive end point of 
pathway performance. Because of the natural history of 
HNC, it was felt that 6 months was an appropriate times-
cale for a patient to re- present or to have had his or her 
deferred assessment expedited and receive a cancer diag-
nosis linked to the referral symptoms. It is acknowledged 
that the standard urgent pathway for suspected HNC re-
ferrals would have had some disruption for those included 
in the current study due to the COVID- 19 pandemic.
The sensitivity and specificity of the HaNC- RC- v2 
in this population were lower than those recorded in the 
validation work that produced the algorithm, although 
the NPV of 97.8% remained high.9,18,19 A number of 
factors may have influenced this difference in algorithm 
performance: the symptom landscape of patients present-
ing to their primary care physicians may have been af-
fected by the pandemic; the referral practices of primary 
care physicians may have been affected by fewer patients 
undergoing face- to- face assessments in primary care4; the 
population differed slightly because this service evaluation 
included only those referred from primary care on the sus-
pected HNC referral pathway and not routine head and 
neck patients who also contributed to the HaNC- RC- v2; 
the primary outcome for the current study was cancer at 
a minimum of 6 months, and this thereby also took into 
account late diagnoses; the overall incidence of cancer in 
this study was lower; patients contributing to the HaNC- 
RC- v2 were also examined, and this may have influenced 
how symptoms were recorded by clinicians20,21; and this 
multicenter, national study involved a greater number of 
clinicians over a wider geographical area than that used to 
generate the HaNC- RC- v2. Further analysis of the data 
collected in this study will help to inform future risk strat-
ification algorithms for suspected HNC referrals under-
going remote triage.
The overall cancer incidence of 5.6% identified in 
this study is consistent with rates reported in the literature 
and by national data sets, which vary between 3.6% and 
11.8%, and it also corresponds with a national trend to-
ward lower incidence rates in this population over time as 
the number of suspected cancer referrals to secondary care 
increases.9,17,22- 24 As the number of referrals increases, 
risk stratification may become even more important for 
Figure 3. Age distribution of (Top) patients with cancer and (Bottom) all suspected head and neck cancer referrals. Note that the 
scales differ by a factor of 10.
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appropriate hospital resource allocation and the identi-
fication of cancers, which represent a diminishing pro-
portion of the referrals coming in. However, burdening 
primary care physicians with collecting and recording 
symptom data for risk stratification is unlikely to be ap-
propriate. First, the referral to secondary care, in part, 
helps to allay patient anxieties because they feel they are 
getting specialist input. Second, accurate and consistent 
recording of symptom data may rely on clinical experi-
ence from a specialist. Indeed, encouraging more referrals 
from primary care is desirable in order to identify cancers 
at an earlier stage in the hope of improving the prognosis 
and/or reducing the treatment intensity.25 Appropriate 
risk stratification could be part of the strategy to handle 
higher volumes of referrals to deliver on these goals in the 
future.
The majority of patients who were felt to have come 
to harm were observed in the deferred group (8 of 11): 
they did not undergo any urgent assessment and were not 
discharged back to primary care. Clinicians may choose 
to monitor a patient’s symptoms to provide an oppor-
tunity for resolution with conservative management or 
a “trial of time,” but this should not be at the expense 
of appropriate examinations and/or investigations in 
higher risk patients. It should be noted that the practice 
of deferring appointments was likely exacerbated by the 
pandemic and reflected prevailing public health advice 
at that time to reduce hospital visits. Certain symptoms 
and practices were identified by this service evaluation as 
being at particular risk of a late diagnosis, and head and 
neck clinicians should be particularly mindful of thoracic 
pathology manifesting with head and neck symptoms 
(Tables 1 and 3). A history of intermittent hoarseness may 
be indicative of a weak vocal cord from a palsied recurrent 
laryngeal nerve brought on by a lung lesion or mediasti-
nal mass, and so it should prompt direct visualization or 
appropriate cross- sectional imaging. Reports of dysphagia 
in the presence of a normal upper aerodigestive tract ex-
amination should prompt urgent esophageal endoscopy 
to rule out more distal lesions.26 This study confirmed 
the finding of a third of cancers on the suspected HNC 
referral pathway being non- HNCs and corroborated pre-
vious reports.23
Limitations
The following limitations are acknowledged: the use of 
only local data may have missed patients who subse-
quently presented to other units; it is not possible to assert 
that consecutive patients were included from all centers 
or submitted by each clinician; local practices may have 
included prescreening of suspected HNC appointments 
to ensure that they were suitable for remote triage; we 
received no data on patients for whom the remote tri-
age and risk stratification process was incomplete; and 
the rate of oral cancer was lower than anticipated and 
reflected low engagement from oral surgery and maxil-
lofacial specialties.
In conclusion, remote triage, augmented by risk 
stratification, was widely adopted in the care of sus-
pected HNC referrals in response to the initial peak of 
the COVID- 19 pandemic. Appropriately implemented, 
it may facilitate more targeted investigations for high- risk 
patients and prevent unnecessary hospital attendance for 
the lowest risk patients. Deferring appointments without 
appropriate escalation to urgent assessment or discharge 
with safety netting may be associated with a particular 
risk of harm.
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